Metabolic agents in the management of diabetic coronary patients: a new era.
Modulation of myocardial free fatty acid metabolism is the key target for metabolic interventions in patients with coronary artery disease (CAD) with diabetes mellitus (DM). Because of its beneficial effects on heart metabolism at rest and on myocardial ischemia and left ventricular function, trimetazidine should be always combined with classical anti-ischemic treatment in patients with DM with CAD. We believe that, the new metabolic agents including L-carnitine, dichloroacetate, perhexiline and etomoxir will be added into our arsenal for the battle against CAD especially in patients with DM in the near future.
Celik
Turgay
T
Kursaklioglu
Hurkan
H
Iyisoy
Atila
A
Jata
Bekim
B
D002331:Carnitine / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000150:complications*; D003999:Dichloroacetic Acid / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004852:Epoxy Compounds / Q000627:therapeutic use; D006801:Humans; D010480:Perhexiline / Q000627:therapeutic use; D014292:Trimetazidine / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D004852:Epoxy Compounds; D014665:Vasodilator Agents; D014803:Vitamin B Complex; D003999:Dichloroacetic Acid; D010480:Perhexiline; C054207:etomoxir; D014292:Trimetazidine; D002331:Carnitine